Structure Encountered
Oak Hill Bio
Develops deprioritized rare disease drugs for underserved patient populations
Oak Hill Bio raised $32.5M to push Roche's shelved Angelman ASO rugonersen into Phase 3.
SIGNAL·Series A financing·$32.5 million Series A·SCORE 65·02 JUN 2026 · 11:54 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / OAK HILL BIO
/ Cambridge, MA, United States
CAPT. / 02.06.26 11:54:29Z
SIGNAL / 65 / 100
Image relayed by The Biotech Voyager during pass over structure Oak Hill Bio. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Oak Hill Bio
Coordinates
Cambridge, MA, United States
Stage
Phase3
Type
Therapeutics
Modalities
ASO · protein therapeutic
Therapeutic area
Rare Disease · Neurology · Ophthalmology
002Signature Detected
FUNDING EVENT
Event type
Series A financing
Magnitude
$32.5 million Series A
Lead investor
Oak Hill Bio
Participating
Co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with KCap Biotechnology Fund
Use of capital
Advance rugonersen (OHB-724) into a pivotal Phase 3 in Angelman syndrome, expected to start mid-2026
003Architecture
PLATFORM PROFILE
Target class
UBE3A-restoring antisense oligonucleotide for Angelman syndrome
Differentiator
Oak Hill buys assets big pharma has set down and tries to finish them, here taking a program Roche walked away from toward a registrational trial in a disease with zero approved drugs
Lead asset
Rugonersen (OHB-724), an antisense oligonucleotide that restores UBE3A expression in neurons, licensed from Roche in 2025
Pipeline depth
Also holds OHB-607, an IGF-1/IGFBP-3 replacement in Phase 2b for complications of extreme prematurity, plus a preclinical diabetic macular edema program
004Voyager Assessment
MACHINE-GENERATED
Oak Hill's whole model is buying what big pharma sets down, and rugonersen is the case study: Roche ran it, paused it, and Oak Hill took it toward Phase 3 in Angelman syndrome, where nothing is approved. The crossover names co-leading the Series A tell you smart money likes the asset. Here is the wrinkle. $32.5 million does not carry an intrathecal ASO through a registrational trial on its own, so read this round as the opening move, not the war chest. Watch for the Phase 3 start and a bigger raise behind it.
005Adjacent Structures
FRONTIER MAP
Ultragenyx GTX-102· Lead Angelman ASOIonis Pharmaceuticals· Angelman ASO ION582Roche· Rugonersen originatorBiogen Spinraza· Approved CNS ASOSCYNEXIS· Revives shelved assetsNeuren Pharmaceuticals· Neurodevelopmental rare disease
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.